South Korea
GC Biopharma to Produce Cholera Vaccines Jointly with Eubiologics
GC Biopharma (006280.KS), a South Korean biopharmaceutical company, announced today that it has signed a MOU at its headquarters in Yongin, South Korea with Eubiologics for a co-production of Euvichol, an oral cholera vaccine.
Curiox Biosystems Inc., Announces Initial Public Offering (IPO)
Curiox Biosystems Inc., a global leader in providing innovative and automated sample preparation solutions for accurate and reproducible cell analysis, announced today the pricing of its initial public offering of 1,400,000 shares of its common stock at a price to the public of 13,000 won per share.
Japanese and Chinese Healthcare Companies Dominate in Asian Capital Market
A review of the top 25 Healthcare companies in Asia-Pacific
Vatech Announces Distribution Through Henry Schein to Help Oral Health Professionals Enhance Access to Cutting-Edge Imaging Solutions
Vatech, a global leader in the dental imaging market, has announced that its products will be distributed by Henry Schein, helping to expand the availability of its cutting-edge products for dental clinics in North America.
SK bioscience Announces Equity Investment in Novavax to Strengthen Strategic Partnership
SK bioscience, an innovative vaccine and biotech company committed to promoting human health from prevention to cure, announced that its board of directors has decided to make an equity investment in Novavax, a global company advancing protein-based vaccines with its novel Matrix-M™ adjuvant, securing 6.5 million shares of common stock through a private placement.
Lemonex announces approval of IND application for mRNA-DegradaBALL vaccine, LEM-mR203, phase 1 clinical trial
Lemonex Inc., a biotechnology company developing innovative messenger RNA (mRNA) and siRNA therapeutics based on a novel nanoparticle drug delivery system announced on the 9th of August that an Investigational New Drug (IND) application has been approved by the Ministry of Food and Drug Safety (MFDS) for mRNA vaccine LEM-mR203 with its nano-drug delivery technology, DegradaBALL® on 21st of July.
Samsung Bioepis & Organon Announce Topline Results from Interchangeability Study of SB5 Humira Biosimilar | Organon
Samsung Bioepis Co., Ltd. and Organon & Co. (NYSE: OGN) today announced topline results from the interchangeability study for SB5, a biosimilar to Humira® (adalimumab). The Phase 4, randomized, double-blind, parallel-group, multiple-dose, active comparator, multicenter clinical study (NCT05510063) for SB5 was conducted across 33 sites in four countries (Bulgaria, Czechia, Lithuania, Poland) from August 2022 to May 2023 in patients with moderate to severe chronic plaque psoriasis.
SK Biopharmaceuticals Assembles ‘Board of Prominent Experts’ to Boost Growth, Innovation
SK Biopharmaceuticals, a global biotech company, announced the formation of its Scientific Advisory Board (SAB), comprising of five prominent experts in oncology, epilepsy, and radiopharmaceutical therapy.
U.S. FDA Accepts Biologics License Application for GC Biopharma’s GC5107B (Immune Globulin Intravenous (Human), 10% Liquid)
GC Biopharma (006280.KS), a global biopharmaceutical company dedicated to specialty plasma-derived therapeutics, today announced that the U.S. Food and Drug Administration (FDA) has accepted the Company's resubmission of the Biologics License Application (BLA) for its GC5107B (Immune Globulin Intravenous (Human) for patients with primary humoral immunodeficiency (PI).
HanAll Biopharma Reports Second Quarter 2023 Financial Results and Provides a Business Update
HanAll Biopharma Co., Ltd. (KRX: 009420. KS), a global biopharmaceutical company committed to discovering and developing innovative medicines for patients, reported financial results for the second quarter and provided business updates.
